Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PBSV and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PBSV and 80,000+ other tickers.
See exactly how PBSV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PBSV and 80,000+ other tickers.
Pharma-Bio Serv, Inc. functions as a specialized consulting firm, providing services focused on regulatory compliance and the transfer of technology. The company offers its compliance expertise to a diverse range of clients, including those in the pharmaceutical, chemical, biotechnology, medical device, cosmetic, and food industries, as well as related product companies. Its operational reach extends across Puerto Rico, the United States, Europe, and Brazil. The firm's technical advisory offerings encompass vital areas such as regulatory adherence, system validation, technology migration…
Pharma-Bio Serv Inc. (OTCMKTS:PBSV - Get Free Report) shares passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $0.53 and traded as low as $0.4225. Pharma-Bio Serv shares last traded at $0.4225, with a volume of 100 shares changing hands. Pharma-Bio Serv Trading Down 21.7%
DORADO, PR / ACCESS Newswire / June 15, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm today announced that revenues for the three and six months ended April 30, 2026 were approximately $2.7 million and $5.0 million, respectively, representing increases of approximately $0.3 million and $0.1 million compared to the same periods last year. Net income for the three and six months ended April 30, 2026, was approximately $0.2 million and $0.3 million, respectively, representing increases of approximately $0.1 million and $0.2 million compared to the same periods last year.
DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2026 were approximately $2.3 million, a decrease of approximately $0.2 million when compared to the same period last year. Net income for the quarter ended January 31, 2026 was $32,860, an improvement of $24,324 when compared to the same quarter last year.
DORADO, PR / ACCESS Newswire / January 29, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2025 were approximately $9.0 million, a decrease of approximately $0.5 million when compared to last year. Additionally, a net loss for the year ended October 31, 2025 was reported of approximately $0.1 million, an improvement of approximately $0.7 million when compared to last year.
ATIF (NASDAQ: ZBAI - Get Free Report) and Pharma-Bio Serv (OTCMKTS:PBSV - Get Free Report) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation. Risk and Volatility ATIF has a beta